$92.53
Today
as of Jul 22, 16:52 ET
Last 30 days
Recent Press Releases & News
Oruka Therapeutics Insider Sold Shares Worth $846,180, According to a Recent SEC Filing
Oruka Therapeutics Insider Sold Shares Worth $472,079, According to a Recent SEC Filing
H.C. Wainwright Keeps Buy Rating on Oruka (ORKA) After Apogee Acquisition News
Overview
52-week range
$11
$91
100% of range
Avg surprise (last 3)
+13.9%
Avg reaction (last 2)
-0.7%
50% positive
Latest IV / EM
94%
EM ±21.6% · $95 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 13, 2026 | Mar/2026 | $-0.48 | $-0.52 | +7.7% | -20.0% | -2.3% | earnings |
| Mon Aug 11, 2025 | Jun/2025 | $-0.46 | $-0.48 | +4.2% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.40 | $-0.57 | +29.8% | — | +0.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.46 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-6.96 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.14 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.10 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 10, 2026 | Jun/2026 | OTHER | -$0.49 | -$0.46 | -6.5% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-36M | — | $-34M | $-28M | $-25M | — | $-29M | $-21M |
| Net income | $-32M | — | $-30M | $-25M | $-21M | — | $-29M | $-22M |
| EPS (diluted) | — | — | — | $-0.46 | $-0.40 | — | $-1.46 | $-6.96 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $50M | $47M | $91M | $65M | $84M | $62M | $411M | $33M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $395M | $344M | $355M | $332M | $352M | $377M | $413M | $34M |
| Total assets | $504M | $489M | $509M | $357M | $377M | $396M | $414M | $34M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $18M | $17M | $22M | $14M | $12M | $14M | $19M | $1M |
| Total equity | $487M | $472M | $487M | $344M | $365M | $382M | $342M | $-29M |